Abstract
Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome of reproductive and metabolic derangements. The combination of anovulation and hyperandrogenism signifies the classic form of PCOS which displays the adverse metabolic phenotype of the syndrome. This phenotype includes visceral obesity and insulin resistance as well as a constellation of other traditional cardiovascular risk factors, mainly low grade inflammation, disturbances of glucose metabolism and dyslipidemia. The resultant increased risk for cardiovascular disease may affect not only obese but also lean women with classic PCOS. The mechanisms underlying the increased cardiovascular risk in the context of PCOS may include not only metabolic aberrations, but also hormonal factors, in particular hyperandrogenemia. However, the consequences in terms of CV morbidity remain questionable due to the difficulties in conducting long-term, prospective studies aimed at identifying potential late-arriving clinical outcomes.
Keywords: PCOS, hyperandrogenism, cardiovascular, metabolism, inflammation.
Current Pharmaceutical Design
Title:Structural, Biochemical and Non-Traditional Cardiovascular Risk Markers in PCOS
Volume: 19 Issue: 32
Author(s): Charikleia Christakou and Evanthia Diamanti-Kandarakis
Affiliation:
Keywords: PCOS, hyperandrogenism, cardiovascular, metabolism, inflammation.
Abstract: Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome of reproductive and metabolic derangements. The combination of anovulation and hyperandrogenism signifies the classic form of PCOS which displays the adverse metabolic phenotype of the syndrome. This phenotype includes visceral obesity and insulin resistance as well as a constellation of other traditional cardiovascular risk factors, mainly low grade inflammation, disturbances of glucose metabolism and dyslipidemia. The resultant increased risk for cardiovascular disease may affect not only obese but also lean women with classic PCOS. The mechanisms underlying the increased cardiovascular risk in the context of PCOS may include not only metabolic aberrations, but also hormonal factors, in particular hyperandrogenemia. However, the consequences in terms of CV morbidity remain questionable due to the difficulties in conducting long-term, prospective studies aimed at identifying potential late-arriving clinical outcomes.
Export Options
About this article
Cite this article as:
Christakou Charikleia and Diamanti-Kandarakis Evanthia, Structural, Biochemical and Non-Traditional Cardiovascular Risk Markers in PCOS, Current Pharmaceutical Design 2013; 19 (32) . https://dx.doi.org/10.2174/1381612811319320011
DOI https://dx.doi.org/10.2174/1381612811319320011 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemokines: Central Mediators of the Innate Response to Sepsis
Current Immunology Reviews (Discontinued) Mesenchymal Stromal Cells: A Promising Cell Source for the Treatment of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Cross Talk Among Leukocytes, Platelets, and Endothelial Cells and its Relevance to Atherosclerosis and Coronary Heart Disease
Current Nutrition & Food Science Proteomics and Mass Spectrometry: What Have We Learned About The Heart?
Current Cardiology Reviews Disease-Induced Neuroinflammation and Depression
CNS & Neurological Disorders - Drug Targets Inflammatory Biomarkers and Therapeutic Targets in Heart Failure
Current Medicinal Chemistry Prediction Models and Scores in Adult Congenital Heart Disease
Current Pharmaceutical Design Editorial: [Statins and Cardiovascular Events in Patients with End-Stage Renal Disease on Hemodialysis. The AURORA Results Suggest the Need for Earlier Intervention]
Current Vascular Pharmacology Propitious Profile of Peppery Piperine
Current Molecular Pharmacology Current Therapeutics, Their Problems and Thiol Metabolism as Potential Drug Targets in Leishmaniasis
Current Drug Metabolism Role of α -Crystallin B in Regulation of Stress Induced Cardiomyocyte Apoptosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Cholesterol Efflux and Reverse Cholesterol Transport: Experimental Approaches
Current Medicinal Chemistry Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Management of Blood Pressure and Heart Rate in Patients with Acute Stroke
Current Pharmaceutical Design PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Pharmacologic Treatment of Pulmonary Arterial Hypertension
Current Pharmaceutical Design Calcium Related Genes in Dogs as Potential Cardiac Biomarkers for the Detection of Chronic Mitral Valve Disease
Recent Patents on Biomarkers New Perspective Therapy of Breast Cancer Based on Selective Dopamine Receptor D2 Agonist and Antagonist Effects on MCF-7 Cell Line
Recent Patents on Anti-Cancer Drug Discovery Primary Prevention of Cardiovascular Risk in Octogenarians by Risk Factors Control
Current Hypertension Reviews iMethylK-PseAAC: Improving Accuracy of Lysine Methylation Sites Identification by Incorporating Statistical Moments and Position Relative Features into General PseAAC via Chou’s 5-steps Rule
Current Genomics